Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2009 Apr;65(4):403-13. doi: 10.1002/ana.21610.

2.

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):230-8. doi: 10.1016/j.jalz.2010.03.008. Review.

3.

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

Kang JH, Korecka M, Figurski MJ, Toledo JB, Blennow K, Zetterberg H, Waligorska T, Brylska M, Fields L, Shah N, Soares H, Dean RA, Vanderstichele H, Petersen RC, Aisen PS, Saykin AJ, Weiner MW, Trojanowski JQ, Shaw LM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):772-91. doi: 10.1016/j.jalz.2015.05.003. Review.

4.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
5.

CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S.

Cochrane Database Syst Rev. 2017 Mar 22;3:CD010803. doi: 10.1002/14651858.CD010803.pub2. Review.

PMID:
28328043
6.

2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Green RC, Harvey D, Jack CR, Jagust W, Luthman J, Morris JC, Petersen RC, Saykin AJ, Shaw L, Shen L, Schwarz A, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jun;11(6):e1-120. doi: 10.1016/j.jalz.2014.11.001. Review.

7.

Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.

Marksteiner J, Hinterhuber H, Humpel C.

Drugs Today (Barc). 2007 Jun;43(6):423-31. Review.

PMID:
17612711
8.

[Biomarkers in Alzheimer's disease].

García-Ribas G, López-Sendón Moreno JL, García-Caldentey J.

Rev Neurol. 2014 Apr 1;58(7):308-17. Review. Spanish.

9.

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment.

Herukka SK, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G.

Alzheimers Dement. 2017 Mar;13(3):285-295. doi: 10.1016/j.jalz.2016.09.009. Epub 2016 Oct 27. Review.

10.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7. Review.

11.

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Blennow K, Vanmechelen E, Hampel H.

Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97. Review.

PMID:
11831556
12.

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Mattsson N, Lönneborg A, Boccardi M, Blennow K, Hansson O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:196-213. doi: 10.1016/j.neurobiolaging.2016.02.034. Review.

PMID:
28317649
13.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2012 Feb;8(1 Suppl):S1-68. doi: 10.1016/j.jalz.2011.09.172. Epub 2011 Nov 2. Review.

14.

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia.

Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G.

Alzheimers Dement. 2017 Mar;13(3):274-284. doi: 10.1016/j.jalz.2016.09.008. Epub 2016 Oct 27. Review.

15.

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.

Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H.

Alzheimers Dement. 2015 Jan;11(1):58-69. doi: 10.1016/j.jalz.2014.02.004. Epub 2014 May 3. Review.

16.

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Blennow K, Hampel H, Weiner M, Zetterberg H.

Nat Rev Neurol. 2010 Mar;6(3):131-44. doi: 10.1038/nrneurol.2010.4. Epub 2010 Feb 16. Review.

PMID:
20157306
17.

Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.

Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ.

Acta Neuropathol. 2010 Sep;120(3):385-99. doi: 10.1007/s00401-010-0723-9. Epub 2010 Jul 22. Review.

18.

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.

Mitchell AJ.

J Neurol Neurosurg Psychiatry. 2009 Sep;80(9):966-75. doi: 10.1136/jnnp.2008.167791. Epub 2009 May 21. Review.

PMID:
19465413
19.

Cerebrospinal fluid biomarkers of Alzheimer's disease.

Fagan AM, Holtzman DM.

Biomark Med. 2010 Feb;4(1):51-63. doi: 10.2217/BMM.09.83. Review.

20.

Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.

Mollenhauer B, Parnetti L, Rektorova I, Kramberger MG, Pikkarainen M, Schulz-Schaeffer WJ, Aarsland D, Svenningsson P, Farotti L, Verbeek MM, Schlossmacher MG.

J Neurochem. 2016 Oct;139 Suppl 1:290-317. doi: 10.1111/jnc.13390. Epub 2016 Feb 10. Review.

Supplemental Content

Support Center